Should I buy or sell Kamada stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KMDA shares. View KMDA analyst ratings or view top-rated stocks .

What is Kamada's stock price target for 2024?

1 Wall Street research analysts have issued twelve-month target prices for Kamada's shares. Their KMDA share price targets range from $11.00 to $11.00. On average, they predict the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 129.9% from the stock's current price. View analysts price targets for KMDA or view top-rated stocks among Wall Street analysts .

How have KMDA shares performed in 2023?

Kamada's stock was trading at $4.01 at the beginning of 2023. Since then, KMDA stock has increased by 19.3% and is now trading at $4.7850. View the best growth stocks for 2023 here .

Are investors shorting Kamada?

Kamada saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 14,100 shares, an increase of 20.5% from the October 31st total of 11,700 shares. Based on an average daily trading volume, of 20,300 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.1% of the shares of the stock are short sold. View Kamada's Short Interest .

When is Kamada's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024. View our KMDA earnings forecast .

How were Kamada's earnings last quarter?

Kamada Ltd. (NASDAQ:KMDA) posted its quarterly earnings data on Wednesday, August, 16th. The biotechnology company reported $0.04 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.02. The biotechnology company had revenue of $37.44 million for the quarter, compared to analysts' expectations of $34.18 million. Kamada had a net margin of 4.07% and a trailing twelve-month return on equity of 5.93%. During the same quarter last year, the business earned $0.07 EPS.

What guidance has Kamada issued on next quarter's earnings?

Kamada updated its FY 2023 earnings guidance on Monday, November, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $138.00 million-$146.00 million, compared to the consensus revenue estimate of $143.83 million.

What other stocks do shareholders of Kamada own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include CA (CA) , BlackRock (BLK) , Endologix (ELGX) , Chipotle Mexican Grill (CMG) , Athabasca Oil (ATH) , Allergan (AGN) , NIC (EGOV) , Micron Technology (MU) , Teva Pharmaceutical Industries (TEVA) and Aegean Marine Petroleum Network (ANW) .

Who are Kamada's major shareholders?

Kamada's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Acadian Asset Management LLC (1.17%), Altshuler Shaham Ltd (0.59%), Meitav Investment House Ltd. (0.17%), Y.D. More Investments Ltd (0.03%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Kamada?

Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Kamada Stock Price, News & Analysis (NASDAQ:KMDA)

$4.78

+0.02 (+0.42%)

(As of 11/28/2023 ET)

Compare

Today's Range: $4.76
▼
$4.82
50-Day Range: $4.14
▼
$5.38
52-Week Range: $3.72
▼
$5.85

Volume: 11,269 shs
Average Volume: 30,060 shs
Market Capitalization: $214.46 million

P/E Ratio: 36.81
Dividend Yield: N/A
Price Target: $11.00

Kamada MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 129.9% Upside
$11.00 Price Target
Short Interest: Healthy
0.05% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.51
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 107.69%
From $0.13 to $0.27 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.60 out of 5 stars

Medical Sector

119th out of 949 stocks

Pharmaceutical Preparations Industry

40th out of 436 stocks

3.5

Analyst's Opinion

Consensus Rating
Kamada has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.00, Kamada has a forecasted upside of 129.9% from its current price of $4.79.
Amount of Analyst Coverage
Kamada has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.05% of the float of Kamada has been sold short.
Short Interest Ratio / Days to Cover
Kamada has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Kamada has recently increased by 20.51%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Kamada does not currently pay a dividend.
Dividend Growth
Kamada does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for KMDA.

2.0

News and Social Media Coverage

News Sentiment
Kamada has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Kamada this week, compared to 1 article on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kamada insiders have not sold or bought any company stock.
Percentage Held by Insiders
36.10% of the stock of Kamada is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 34.08% of the stock of Kamada is held by institutions.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Kamada are expected to grow by 107.69% in the coming year, from $0.13 to $0.27 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kamada is 36.81, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 117.96.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kamada is 36.81, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 111.50.
Price to Book Value per Share Ratio
Kamada has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Kamada Stock (NASDAQ:KMDA)

Kamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. It has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. Kamada Ltd. was incorporated in 1990 and is headquartered in Rehovot, Israel.

KMDA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KMDA Stock News Headlines

November 25, 2023 | americanbankingnews.com

Kamada (NASDAQ:KMDA) Share Price Crosses Below Two Hundred Day Moving Average of $5.06

November 18, 2023 | americanbankingnews.com

Kamada's (KMDA) Buy Rating Reiterated at HC Wainwright

November 28, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 15, 2023 | finance.yahoo.com

KMDA: $37.9 Million in 3Q23 Revenues; Closes $60 Million Private Placement with FIMI Opportunity Funds…

November 14, 2023 | benzinga.com

Kamada Stock (NASDAQ:KMDA) Earnings Dates and Earning Calls

November 13, 2023 | msn.com

Kamada beats Q3 top and bottom line estimates; reaffirms FY23 outlook

November 13, 2023 | finance.yahoo.com

Kamada: Q3 Earnings Snapshot

November 12, 2023 | markets.businessinsider.com

Here's what Wall Street expects from Kamada's earnings report

November 28, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 10, 2023 | msn.com

Kamada Q3 2023 Earnings Preview

November 9, 2023 | msn.com

Football: Kamada, Doan recalled for Japan's World Cup qualifiers

November 8, 2023 | finance.yahoo.com

Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023

October 10, 2023 | finanznachrichten.de

Kamada Ltd.: Kamada Provides Corporate Update on its Israel Operations

October 10, 2023 | marketwatch.com

Kamada Operations Continuing in Israel

October 10, 2023 | finance.yahoo.com

Kamada Provides Corporate Update on its Israel Operations

August 30, 2023 | finance.yahoo.com

Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds

August 21, 2023 | finance.yahoo.com

KMDA: 2Q23 Revenues up 59% YoY; Reiterates 2023 Revenue Guidance of $138 Million to $146 Million…

August 16, 2023 | finanznachrichten.de

Kamada Ltd.: Kamada Reports Strong Second Quarter and First Half 2023 Financial Results; Reiterates 2023 Revenue and Profitability Guidance

August 16, 2023 | markets.businessinsider.com

Kamada Reports Strong Second Quarter and First Half 2023 Financial Results; Reiterates 2023 Revenue and Profitability Guidance

August 16, 2023 | sfgate.com

Kamada: Q2 Earnings Snapshot

August 15, 2023 | markets.businessinsider.com

Kamada earnings preview: what to expect

August 9, 2023 | finance.yahoo.com

Kamada to Announce Second Quarter and First Half Ended June 30, 2023 Financial Results and Host Conference Call on August 16, 2023

August 5, 2023 | msn.com

Football: Kamada seals move to Lazio in Italian Serie A

August 3, 2023 | msn.com

Football: Japan midfielder Kamada headed to Lazio: Reports

July 12, 2023 | msn.com

Spurs: Lilywhites have long-standing Kamada interest

July 11, 2023 | msn.com

Spurs: Daichi Kamada could be Maddison's perfect partner

June 21, 2023 | msn.com

Kamada: Deep Dive Following FIMI Placement, Rate Buy

See More Headlines

Receive KMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kamada and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/16/2023
Today: 11/28/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/20/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KMDA
CUSIP: N/A
CIK: 1567529
Web: www.kamada.com
Phone: (728) 940-6472
Fax: 972-8940-6473
Employees: 380
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.00
High Stock Price Target: $11.00
Low Stock Price Target: $11.00
Potential Upside/Downside: +129.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.13
Trailing P/E Ratio: 36.81
Forward P/E Ratio: 36.81
P/E Growth: N/A
Net Income: $-2,320,000.00
Net Margins: 4.07%
Pretax Margin: 4.19%
Return on Equity: 5.93%
Return on Assets: 3.52%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.11
Quick Ratio: 2.13

Sales & Book Value

Annual Sales: $129.34 million
Price / Sales: 1.66
Cash Flow: $0.03 per share
Price / Cash Flow: 183.16
Book Value: $3.93 per share
Price / Book: 1.22

Miscellaneous

Outstanding Shares: 44,820,000
Free Float: 28,640,000
Market Cap: $214.46 million
Optionable: Not Optionable
Beta: 0.95

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Amir London (Age 54)
Chief Executive Officer
Comp: $619k
Mr. Chaime Orlev (Age 53)
Chief Financial Officer
Comp: $396k
Mr. Eran Nir (Age 50)
Chief Operating Officer
Comp: $371k
Mr. Boris Gorelik (Age 42)
Vice President of Business Development & Strategic Programs
Comp: $337k
Mr. David Tsur (Age 73)
Co-Founder & Deputy Chairman of the Board
Comp: $252k
Mr. Nir Livneh B.A. (Age 44)
L.L.B., VP, General Counsel & Corporate Secretary
Ms. Hanni Neheman (Age 53)
Vice President of Marketing & Sales
Ms. Liron Reshef (Age 52)
Vice President of Human Resources
Mr. Jon R. Knight
Vice President of US Commercial Operations
Ms. Shavit Beladev
Vice President of Kamada Plasma

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

KMDA Stock Analysis - Frequently Asked Questions

Should I buy or sell Kamada stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KMDA shares.
View KMDA analyst ratings or view top-rated stocks.
What is Kamada's stock price target for 2024?: 1 Wall Street research analysts have issued twelve-month target prices for Kamada's shares. Their KMDA share price targets range from $11.00 to $11.00. On average, they predict the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 129.9% from the stock's current price.
View analysts price targets for KMDA or view top-rated stocks among Wall Street analysts.
How have KMDA shares performed in 2023?: Kamada's stock was trading at $4.01 at the beginning of 2023. Since then, KMDA stock has increased by 19.3% and is now trading at $4.7850.
View the best growth stocks for 2023 here.
Are investors shorting Kamada?: Kamada saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 14,100 shares, an increase of 20.5% from the October 31st total of 11,700 shares. Based on an average daily trading volume, of 20,300 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.1% of the shares of the stock are short sold.
View Kamada's Short Interest.
When is Kamada's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our KMDA earnings forecast.
How were Kamada's earnings last quarter?: Kamada Ltd. (NASDAQ:KMDA) posted its quarterly earnings data on Wednesday, August, 16th. The biotechnology company reported $0.04 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.02. The biotechnology company had revenue of $37.44 million for the quarter, compared to analysts' expectations of $34.18 million. Kamada had a net margin of 4.07% and a trailing twelve-month return on equity of 5.93%. During the same quarter last year, the business earned $0.07 EPS.

What guidance has Kamada issued on next quarter's earnings?: Kamada updated its FY 2023 earnings guidance on Monday, November, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $138.00 million-$146.00 million, compared to the consensus revenue estimate of $143.83 million.
What other stocks do shareholders of Kamada own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), NIC (EGOV), Micron Technology (MU), Teva Pharmaceutical Industries (TEVA) and Aegean Marine Petroleum Network (ANW).
Who are Kamada's major shareholders?: Kamada's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Acadian Asset Management LLC (1.17%), Altshuler Shaham Ltd (0.59%), Meitav Investment House Ltd. (0.17%), Y.D. More Investments Ltd (0.03%) and Concourse Financial Group Securities Inc. (0.00%).
How do I buy shares of Kamada?: Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:KMDA) was last updated on 11/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial